We narrowed to 31,337 results for: PLE;

#35509-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP (#35509). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin E123T/T159C mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Feb. 21, 2018

Academic Institutions and Nonprofits only

#35509-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP (#35509). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin E123T/T159C mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Feb. 21, 2018

Academic Institutions and Nonprofits only

#55634-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. EF1a-driven mCherry and bicistronic Flp recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

May 31, 2019

Academic Institutions and Nonprofits only

#55632-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-mCherry-IRES-Cre (#55632). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry-IRES-Cre plasmid DNA. Cre and bicistronic (IRES) mCherry expression under the EF1a promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Aug. 30, 2017

Academic Institutions and Nonprofits only

#55645-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent Channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 23, 2018

Academic Institutions and Nonprofits only

#55645-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 2, 2019

Academic Institutions and Nonprofits only

#55645-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

June 8, 2020

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only

#55634-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-mCherry-IRES-Flpo (#55634). In addition to the viral particles, you will also receive purified pAAV-EF1a-mCherry-IRES-Flpo plasmid DNA. Flpo and bicistronic (IRES) mCherry expression under the EF1a promoter. These AAV preparations are suitable purity for injection into animals. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

July 17, 2017

Academic Institutions and Nonprofits only

#55645-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent Channelrhodopsin-EYFP expression for optogenetic activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 5, 2017

Academic Institutions and Nonprofits only